SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, has introduced the first 5.5 ml prefillable staked-needle glass syringe to the market. As part of the company’s syriQ BioPure platform, this new large-volume syringe facilitates the shift towards large-volume drug delivery devices for biologic therapies administered at home. It is particularly essential for treatments in areas such as immunology, oncology, and central nervous system disorders.
“This portfolio expansion marks a significant step for SCHOTT Pharma in advancing the trend of self-administering substantial drug doses subcutaneously at home. With device-compatible large-volume options across all our product ranges and collaborations with leading device manufacturers, we provide pharma companies with solutions to efficiently scale homecare offerings and expedite their market entry,” states Andreas Reisse, CEO of SCHOTT Pharma.
SCHOTT Pharma will present its full portfolio of large-volume drug containment and delivery solutions from October 28 to 30 at the CPHI tradeshow in Frankfurt am Main, Germany.
The global large-volume injectors market is expected to witness substantial growth over the next decade, driven by factors such as the rising prevalence of chronic diseases, a shift towards homecare, and technological advancements in injector devices. This progress is accompanied by a transition from intravenous to subcutaneous drug administration, which offers cost benefits to healthcare systems and ensures safe and comfortable home injections for numerous patients, albeit requiring drug reformulation efforts from pharmaceutical companies and the development of new large-volume delivery solutions.
Addressing this market demand, SCHOTT Pharma is expanding its product range with large-volume solutions. The new 5.5 ml large-volume prefillable stake-needle glass syringe supplements the syriQ BioPure platform and is designed to store and deliver large volumes of complex biologics and highly sensitive drugs. Manufactured using specialised technology, these syringes maintain ultra-low tungsten levels, minimising drug-container interaction risks throughout the product’s shelf life. Designed for optimal functionality, they ensure treatment continuity at home and efficiency while seamlessly integrating with autoinjectors, offering safe and simple drug administration for patients.
SCHOTT Pharma’s syriQ BioPure 5.5 ml glass syringe is compatible with Datwyler’s latest plunger and Ypsomed's YpsoMate 5.5 ml large-volume autoinjector. “By integrating SCHOTT Pharma's new large-volume glass syringe into our YpsoMate 5.5 autoinjector, Ypsomed is driving the move into the large-volume segment. This step underscores our strong long-term partnership with SCHOTT Pharma and our dedication to swiftly bringing innovative, patient-friendly injection systems to market. With this collaboration, we actively enable clinical studies and accelerate the introduction of various large-volume therapies to the market,” says Ulrike Bauer, Chief Business Officer (CBO) from Ypsomed.
With this launch, SCHOTT Pharma continues to advance its mission of enhancing patient care and facilitating the widespread adoption of homecare solutions worldwide.
